HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors
- Name
- HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors
- Accession Number
- DBCAT005728
- Description
Not Available
- ATC Classification
- Drugs
Drug Drug Description Trastuzumab A monoclonal anti-human epidermal growth factor receptor 2 protein antibody used to treat HER2-positive breast, gastroesophageal, and gastric cancers. Trastuzumab emtansine An antineoplastic agent and antibody-drug conjugate used to treat HER2-overexpressing breast cancer. Pertuzumab An antineoplastic agent used in the treatment of HER2-positive metastatic breast cancer in combination with other antineoplastic agents. Trastuzumab deruxtecan An antibody used to treat certain types of unresectable or metastatic HER2 positive breast cancer. Trastuzumab duocarmazine Trastuzumab duocarmazine is under investigation in clinical trial NCT03262935 (SYD985 vs. Physician's Choice in Participants With Her2-positive Locally Advanced or Metastatic Breast Cancer). Margetuximab An Fc-engineered human/mouse chimeric IgG1κ anti-HER2 monoclonal antibody indicated for patients with HER2-positive metastatic breast cancer. - Drugs & Drug Targets